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Abstract Intracerebral hemorrhage is the second most com-
mon subtype of stroke. In recent decades our understanding
of intracerebral hemorrhage has improved. New risk factors
have been identified; more knowledge has been obtained on
previously known risk factors; and new imaging techniques
allow for in vivo assessment of preclinical markers of intra-
cerebral hemorrhage. In this review the latest developments
in research on intracerebral hemorrhage are highlighted
from an epidemiologic point of view. Special focus is on
frequency, etiologic factors and pre-clinical markers of in-
tracerebral hemorrhage.
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Introduction
Stroke is the second leading cause of death worldwide,
and one of the leading causes of disability [1, 2]. With
increasing life expectancy the burden of stroke is likely
to increase worldwide with middle and low income
countries particularly affected [3, 4]. Intracerebral hemor-
rhage is the second most common subtype of stroke after
ischemic stroke and accounts for approximately 10 % to
20 % of all strokes [5].
Intracerebral hemorrhage occurs when a blood vessel
within the brain parenchyma ruptures. Intracerebral hemor-
rhage can occur as a complication of a pre-existing lesion,
such as vascular malformation or tumor, which is then
referred to as secondary intracerebral hemorrhage. Primary
intracerebral hemorrhage refers to intracerebral hemorrhage
in the absence of a single clear underlying lesion and is the
most frequent type of intracerebral hemorrhage. This review
focuses on primary intracerebral hemorrhage .
Over the last decades much progress has been made in
understanding stroke, though most research has focused on
ischemic stroke. Nevertheless, steady progress has also been
made in unravelling the causes of intracerebral hemorrhage.
In recent years new risk factors for intracerebral hemorrhage
have emerged; our understanding of known risk factors has
improved; newer imaging techniques have allowed for iden-
tification of putative pre-clinical markers of intracerebral
hemorrhage; and better treatment options have allowed for
longer survival among patients suffering from intracerebral
hemorrhage. Epidemiologic studies have played an essential
role in these developments.
This review provides an overview of these recent epide-
miologic developments in understanding intracerebral
hemorrhage. The focus is on frequency, risk factors, pre-
clinical markers, and prognostic indicators of intracerebral
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hemorrhage. Finally, we make a few recommendations for
future epidemiologic research on intracerebral hemorrhage.
Frequency of Intracerebral Hemorrhage
Whereas the age-standardized frequency of all stroke has
decreased in the past decades, this decrease has primarily
been driven by ischemic stroke [5]. Data on temporal trends
for intracerebral hemorrhage are conflicting with some stud-
ies reporting a decrease in intracerebral hemorrhage in the
last two decades [6, 7], whereas other studies show stable
numbers in the same time period [8, 9], and yet other studies
show an increase [10, 11]. Given the temporal trends in risk
factors for intracerebral hemorrhage, one explanation for the
conflicting results across studies is that the number of intra-
cerebral hemorrhages due to hypertension has decreased in
time due to better treatment, but is offset by an increase in
number of intracerebral hemorrhages related to warfarin use
[12]. Combining all available incidence data, a large meta-
analysis recently concluded that most likely the incidence of
intracerebral hemorrhage has not changed between 1980
and 2006 [13••]. The overall incidence during this time
period was 24.6 per 100.000 person-years (95 % confidence
interval 19.7–30.7), ranging from 1.8 to 129.6 per 100.000
person-years across studies. Among all studies included in
that meta-analysis the incidence of intracerebral hemorrhage
in Asian populations was almost twice that in other ethnic-
ities (i.e. Black, Indian, Hispanic, Maori, White). Moreover,
the incidence was 15 % lower in women than men, though
not statistically significant (95 % confidence interval from
39 % decrease to 18 % increase). Consistent across studies
was the finding that the incidence of intracerebral hemor-
rhage increased strongly with age, with persons aged
85 years and over having an almost ten-fold increase in
yearly risk of intracerebral hemorrhage compared to persons
aged 45 to 54 years [13••].
Risk Factors
Much of the epidemiologic research on intracerebral hem-
orrhage has concentrated on identifying risk factors for
intracerebral hemorrhage. Not only do risk factors provide
etiologic insights into disease, but in case of modifiable risk
factors, these can also become targets for preventive or
therapeutic strategies. Moreover, risk factors can be utilized
for their predictive or diagnostic value. This latter notion
also brings forth an important methodological consideration
in epidemiologic studies on intracerebral hemorrhage. Clin-
ically, intracerebral hemorrhage is usually subtyped accord-
ing to location into lobar or deep intracerebral hemorrhage
[14]. This distinction is based on the presumed underlying
etiology with lobar intracerebral hemorrhage thought to be
caused primarily by cerebral amyloid angiopathy, and deep
intracerebral hemorrhage more related to hypertensive vas-
culopathy. Similarly, another distinction of intracerebral
hemorrhage is based on whether or not the intracerebral
hemorrhage is related to warfarin use [7, 10, 14]. Whereas
such distinctions may be useful in a clinical setting for
prognostic and therapeutic stratification, for etiologic re-
search it is important to note that intracerebral hemorrhage
is a complex disease with multiple underlying etiologies and
risk factors. An intracerebral hemorrhage is not caused by a
single risk factor, but is more likely to be a result of a
complex interplay of multiple risk factors—though a single
or few risk factors may have a bigger role than others.
Therefore, any distinction of intracerebral hemorrhage based
on a single presumed underlying risk factor may preclude
identification of additional risk factors. Nevertheless, having
said this, we also note that such distinctions are useful if the
aim is to identify risk factors that act in concert with either
cerebral amyloid angiopathy or hypertension.
Hypertension
Abundant evidence, both from case–control studies and
cohort studies, shows that hypertension is the single most
important risk factor for intracerebral hemorrhage [15, 16••].
Most of the intracerebral hemorrhages due to hypertension
are thought to occur deep in the brain parenchyma, although
associations with lobar intracerebral hemorrhage have been
reported [17]. A meta-analysis across 11 case–control stud-
ies revealed that hypertensives had an almost 3.5-fold in-
creased risk of intracerebral hemorrhage compared with
normotensives [15]. Another meta-analysis showed that
self-reported hypertension or a measured blood pressure of
>160/90 increased the risk of intracerebral hemorrhage more
than ninefold [16••]. It should be noted that these risk
estimates were not adjusted for potential confounding vari-
ables. Therefore, the true risk increase due to hypertension is
likely to be smaller, but nevertheless still very substantial.
The increased risk associated with blood pressure does
not seem to be restricted to clinical hypertension. Studies
have shown that blood pressure increases within the normal
range are also associated with a linear increase in the risk of
intracerebral hemorrhage [18].
Given the strength of association, the high prevalence of
hypertension, and the readily available treatment options,
blood pressure control is considered the main option for
prevention of intracerebral hemorrhage.
Smoking
Studies have consistently shown tobacco use as a risk factor
for intracerebral hemorrhage [19, 20], though the effect size
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is not as large as for hypertension. These studies almost
exclusively focus on cigarette smoking, but there is no
reason not to generalize these findings to other modes of
tobacco use, such as pipes and cigars [21].
Studies have demonstrated a dose–response relationship
with the number of cigarettes smoked and risk of intracere-
bral hemorrhage. Moreover, the effect of smoking extends
to former smoking, albeit the risk is largest for current
smokers. The reported relative risk of current smokers ver-
sus non-smokers lies between 1.3 and 1.5 [15, 16••].
Alcohol
Because the definition of high alcohol intake differs across
various studies, it has been difficult to provide summary
measures in meta-analyses. Nevertheless, there is compelling
evidence relating high alcohol intake with a higher risk of
intracerebral hemorrhage [15, 16••, 19]. Presumed pathways
for this association include platelet dysfunction, coagulation
disturbances, or endothelial damage. It is noteworthy that
whereas for ischemic stroke moderate alcohol intake has been
shown to be protective, the risk of intracerebral hemorrhage is
increased suggesting a linear dose–response relationship be-
tween alcohol intake and intracerebral hemorrhage risk [19].
Cholesterol and Lipids
Increasing evidence from longitudinal studies suggests that
hypercholesterolemia is associated with a lower risk of
intracerebral hemorrhage [22, 23]. This is in contrast to
earlier case–control studies that implicated high cholesterol
as risk factor for intracerebral hemorrhage [24]. The exact
mechanism is still unclear but low cholesterol is thought to
weaken the endothelial wall. More recent studies have in-
vestigated not only cholesterol, but several lipid fractions.
These studies suggest that the associations with lipids are
mainly driven by low triglyceride levels [25•]. How
triglyceride levels lead to intracerebral hemorrhage still
remains unclear.
Diabetes Mellitus
Diabetes mellitus is of increasing interest as risk factor for
intracerebral hemorrhage given the potential for relatively
easy intervention and prevention strategies. A large meta-
analysis of 102 prospective studies, including 698.782 par-
ticipants, recently provided convincing evidence for diabe-
tes as risk factor for intracerebral hemorrhage [26]. The
reported relative risk was 1.6 (95 % confidence interval
from 1.2 to 2.1) for persons with diabetes compared to
persons without diabetes. There is also evidence from other
studies implicating diabetes mellitus as risk factor for intra-
cerebral hemorrhage [15].
Cerebral Amyloid Angiopathy
After hypertension, the single most important risk factor for
intracerebral hemorrhage is thought to be cerebral amyloid
angiopathy. Cerebral amyloid angiopathy refers to the accu-
mulation of β-amyloid in the media and adventitia of mostly
cortical vessels, which can lead to leakage of blood through
the vessel wall [27••]. Given the distribution of cerebral
amyloid angiopathy, these intracerebral hemorrhage usual-
ly—though not exclusively—occur in the cortical brain
regions, referred to as lobar intracerebral hemorrhage. The
frequency of cerebral amyloid angiopathy is thought to
increase with age, with almost half of all persons older than
90 showing some signs of cerebral amyloid angiopathy.
Current estimates show that almost 50 % of intracerebral
hemorrhages in a lobar region are related to amyloid angi-
opathy [28]. Although this percentage is high for a single
risk factor, it is important to keep in mind that the remaining
50 % are caused by other risk factors, many of which are
still unidentified. Apart from intracerebral hemorrhage, cere-
bral amyloid angiopathy also increases the risk of Alzheimer’s
disease, suggesting partly overlapping mechanisms between
intracerebral hemorrhage and Alzheimer’s disease [27••].
Most research on cerebral amyloid angiopathy currently
focuses on its early identification and risk stratification
based on any such early markers (see section on pre-clinical
imaging markers). However, the causes of cerebral amyloid
angiopathy are still unknown. Apart from genetic influences
no clear modifiable risk factors have been identified to date
(see section on genetic risk factors). Therefore, primary
prevention opportunities related to cerebral amyloid angiop-
athy as risk factor for intracerebral hemorrhage are limited.
Medication
Anticoagulant use, especially warfarin, is considered a risk
factor of intracerebral hemorrhage. Evidence for this asso-
ciation comes from various sources [7, 10]. It is important to
note, however, that benefits of warfarin far outweigh the
increased risk of intracerebral hemorrhage associated with
it. Still, this demonstrates the urgent need for better risk
stratification strategies in order to better balance the benefits
and adverse events associated with warfarin use. Given that
warfarin use has rapidly increased in the last decades, stud-
ies have also shown a drastic increase in intracerebral hem-
orrhage related to warfarin use [10], though this notion is
contested by other studies [7]. The increased risk of intra-
cerebral hemorrhage related with anticoagulants also
extends to other coumarin derivatives, such as acenocou-
marol and fenprocoumon, which are more often used than
warfarin in European settings [29]. Data on other anticoa-
gulants are scarce, though there is a suggestion of an in-
creased risk of intracerebral hemorrhage related with direct
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thrombin inhibitors [30]. However, more data are needed
before a more conclusive judgement can be made.
Likewise, a large meta-analysis showed that aspirin use
increases the risk of intracerebral hemorrhage [31], though
here too the benefits of aspirin far outweigh the potential
risks associated with its use.
Genetic Risk Factors
Evidence for a genetic predisposition for intracerebral hemor-
rhage comes from family studies. Several single-gene disorders
leading to intracerebral hemorrhage have been identified, and
include familial cerebral amyloid angiopathy due to mutations in
the APP gene and cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL)
due to mutations in the NOTCH3 gene [32]. However, these
monogenetic disorders are rare and explain only a small propor-
tion of the genetic predisposition of intracerebral hemorrhage.
Instead, the genetics of primary intracerebral hemorrhage
are thought to be more complex with many other genes
involved each with a small individual effect [32]. Because
of their modest effect sizes, many of such genes are still
unidentified. So far, only the APOE gene has been identified
as a robust genetic risk factor for intracerebral hemorrhage.
APOE is considered a strong risk factor for cerebral amyloid
angiopathy and it is for a large part via this underlying
etiology that APOE relates with intracerebral hemorrhage
[27••]. However, APOE has also been shown to affect blood
vessels via other mechanisms.
Apart from APOE, many other candidate genes have
been implicated, although evidence for such genes has been
limited. These genes include ACE, APOH, Factor VII and
Factor XIII, and IL-6 [32]. The advent of genome-wide
association studies, in which hundreds of thousands of ge-
netic markers are tested concomitantly, provides a unique
opportunity to identify additional genes with modest effects.
The success and feasibility of genome-wide association
studies has already been demonstrated in ischemic stroke
and dementia [33, 34]. However, the necessity of having
large sample sizes currently limits the full potential of
genome-wide association studies for intracerebral hemor-
rhage. Nevertheless, CR1, a novel gene for Alzheimer’s
disease identified using genome-wide association studies,
has also been implicated in intracerebral hemorrhage [35].
Emerging Risk Factors
Apart from the aforementioned risk factors, for which asso-
ciations are robust and have been established, there are
several other putative risk factors for which a solid body
of evidence is emerging.
Regular physical activity has been suggested to be pro-
tective of intracerebral hemorrhage, though studies have not
shown conclusive evidence [16••, 36]. Dietary factors have
been implicated in intracerebral hemorrhage, although it is
still unclear which dietary constituents drive this association
[19, 37].
Emerging evidence further shows that poor kidney func-
tion is a novel risk factor for stroke, including intracerebral
hemorrhage [38]. This risk is not only restricted to patients
with overt kidney disease, but seemingly extends to the
general population. However, it is worth noting that not all
studies find associations between markers of kidney disease
and intracerebral hemorrhage [39]. This shows the need for
further studies on this relationship.
There is also increasing interest in body-mass index as
risk factor for intracerebral hemorrhage [40], though it is
likely not a direct cause but rather an indicator of an under-
lying process. Interestingly, both low and high body mass
index increase the risk of intracerebral hemorrhage [40].
Pre-Clinical Imaging Markers
Given the potential public health impact of early identifica-
tion of persons at high-risk of intracerebral hemorrhage,
many epidemiological studies have focused on identifying
pre-clinical non-invasive imaging markers for intracerebral
hemorrhage. We focus here on two promising markers that
are related to magnetic resonance imaging (MRI) of the
brain and retinal imaging.
Cerebral Microbleeds on Magnetic Resonance Imaging
In recent years, newer MRI techniques have led to the
discovery of cerebral microbleeds [41•]. These are small
loci of chronic blood products in brain tissue, caused by
leakage of blood vessels. Studies have shown a high prev-
alence and incidence of these lesions, both in a clinical
setting and in the general elderly population [42, 43]. Given
the presumed overlapping etiology, microbleeds are of in-
terest as putative precursors of intracerebral hemorrhage. In
line with this, microbleeds are also categorized into deep
and lobar according to the presumed underlying cause: there
are compelling data relating lobar microbleeds to cerebral
amyloid angiopathy and deep microbleeds to hypertensive
vasculopathy [41•]. Recent studies have also found similar-
ities between intracerebral hemorrhage and microbleeds
with regard to shared risk factors, i.e. APOE, hypertension,
and lipid profile [25•, 44]. However, not only is it of interest
to investigate shared risk factors, but also to focus on non-
overlapping risk factors and to assess to what extent these
point towards a different pathology underlying microbleeds
and intracerebral hemorrhage.
With regards to clinical outcomes of cerebral micro-
bleeds, several clinical studies among stroke patients have
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related microbleeds to the risk of (recurrent) intracerebral hem-
orrhage [27••]. Moreover, given the overlap between cerebral
amyloid angiopathy and Alzheimer pathology, microbleeds
have also been associated with Alzheimer’s disease [45].
Still, to fully establish cerebral microbleeds as precursor
(and thus predictor) of intracerebral hemorrhage population-
based longitudinal studies are needed, which are currently
lacking. In coming years, the exact role of microbleeds as
putative pre-clinical marker of intracerebral hemorrhage is
set to be established.
Retinal Imaging
The retinal vasculature shares many morphologic and phys-
iologic properties with intracerebral vasculature. Because
the retinal vasculature is easily accessible in vivo using
retinal imaging, there is an increasing interest to use the
retina as model to study pathologic changes in the cerebral
vasculature. Retinal signs that have been associated with
intracerebral hemorrhage include retinal vessel calibres,
signs of age-related macular disease, retinopathy, focal nar-
rowing of arterioles, and arteriovenous nicking [46–48].
However, many of these signs are not specific for intracere-
bral hemorrhage and have also been associated with ische-
mic stroke and its subtypes. Therefore, despite convincing
associations, the predictive accuracy of retinal imaging for
risk of intracerebral hemorrhage is yet to be determined.
Prognosis after Intracerebral Hemorrhage
Despite aggressive and newer management strategies, the
prognosis of patients with intracerebral hemorrhage remains
very poor: case-fatality at 1 month is over 40 % and has not
improved in the last decades [13••]. Similarly, of those who
survive only a small proportion reaches independent life
after 1 year, with estimates varying between 12 % and
39 % [13••]. These numbers show that intracerebral hemor-
rhage is not only a very lethal disease, but that remaining
survivors pose a significant burden on health care resources.
It is worth noting that most studies investigating prognosis
of intracerebral hemorrhage do so until 1 year after intracere-
bral hemorrhage [20, 49]. Very few studies have investigated
long-term prognosis of intracerebral hemorrhage beyond
3 years [50], usually because people are discharged from
clinical follow-up. It remains to be seen therefore, whether
the adverse prognosis after intracerebral hemorrhage remains
poor or stabilizes in the long-term. Population-based studies
would provide an ideal setting to study the long-term progno-
sis after intracerebral hemorrhage, given their better follow-up
of patients that discontinue clinical evaluations. In this light, it
would be equally interesting to investigate determinants of
long-term prognosis after intracerebral hemorrhage.
Conclusions
Intracerebral hemorrhage is a multi-factorial disease caused by
several interacting and overlapping risk factors and etiologies.
Hypertension remains the most important risk factor followed
by cerebral amyloid angiopathy. However, the increased use
of anticoagulants poses new challenges to better prevent in-
tracerebral hemorrhage as complication. Emerging risk factors
have also been identified providing new pathways for further
research. New imaging techniques will in coming years be
assessed for their ability to identify persons at an increased
risk of intracerebral hemorrhage, which will substantially
improve pre-clinical risk-stratification.
However, despite these advances, intracerebral hemor-
rhage still poses a substantial burden on healthcare systems.
More worryingly, over the last decades the incidence and
prognosis of intracerebral hemorrhage have remained stable.
This indicates that there is still a long way to go before
we have a full understanding of intracerebral hemorrhage.
Epidemiologic research will continue to be one of the
cornerstones in research on intracerebral hemorrhage.
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